3M Company (MMM) Quote

Firefighters sue 3M/DD/HON re PFAS-laden gear:

https://finance.yahoo.com/news/connecticut-firefighters-sue-dupont-3m-214455035.html

3M +4% to 12m high because they cut the dividend by 54%*. Part of the reason for the cut was the spinoff of SOLV, but most of the reason for the cut was to improve the balance sheet and be better able to afford the PFAS and earplug legal liabilities that have been settled.

*The new annualized payout is $2.80, down from $6.04. At the current share price ($104.86), the new annualized payout is a yield of 2.7%.

Barron’s—>3M has turned_the_corner_and_is_now_a strong buy:

https://www.barrons.com/articles/buy-3m-stock-price-pick-4bc973b4

FWIW

3M 1Q24 CC transcript:

https://finance.yahoo.com/news/q1-2024-3m-co-earnings-045004671.html

3M reports 1Q24 results—issues 2024 ex-SOLV-spin guidance:

https://d1io3yog0oux5.cloudfront.net/_827c8a8b5aa9802496746200b47d1a06/3m/db/3222/30862/earnings_release/Q1+2024+Press+Release.pdf

3M spun off its healthcare segment into the new company, Solventum (Nasdaq: SOLV) on 4/1/23, so 3M’s 1Q24 results include that business segment. However, 3M’s new guidance for full-year 2024 results excludes the spun-off business and is on an apples-to-apples basis.

1Q24 sales were $8.0B, flat YoY. 1Q24 organic sales (excluding FX, acquisitions, and divestitures) were -1% YoY.

1Q24 non-GAAP EPS—which excludes the cost of the announced earplug and PFAS settlements and related legal expenses—was $2.39, up from $1.97 in 1Q23.

3M’s new ex-SOLV-spin 2024 guidance is as follows:

Non-GAAP EPS of $6.80-7.30. (The prior 2024 guidance including SOLV was $9.35-9.75; actual 2023 non-GAAP EPS was $9.24.)

Sales growth of -0.25% to +1.75%]/b].

Organic sales growth of 0-2.0%.


CC slides:
https://d1io3yog0oux5.cloudfront.net/_827c8a8b5aa9802496746200b47d1a06/3m/db/3222/30862/presentation/Q1+2024+Earnings+Presentation.pdf

Financial statements: https://d1io3yog0oux5.cloudfront.net/_827c8a8b5aa9802496746200b47d1a06/3m/db/3222/30862/financial_statement/Q1+2024+Supplemental+Financial+Schedules.pdf

Bought 5 July 100 calls here today at 1.75, earnings out in the morning!

Great info
Next day settlement begins 5/28 per SEC mandate

Very nice!

iHub has a board for the SOLV spinoff:

https://investorshub.advfn.com/Solventum-Corp-SOLV-42765

3M Company (MMM) recently completed the previously announced spin-off of its healthcare business into a separate public company. The spun-off entity, which is renamed Solventum Corporation, is listed on the NYSE under the ticker SOLV.

https://www.zacks.com/stock/news/2249069/3m-mmm-completes-divestiture-of-its-healthcare-business

MMM’s shares increased 6% yesterday to eventually close the trading session at $94.02.

MMM shareholders received one share of Solventum stock for every four shares of 3M stock held on the record date for the distribution, Mar 18, 2024. The distribution is proposed to be tax-free to MMM’s shareholders. It’s worth noting that 19.9% of outstanding shares of Solventum stock were retained by 3M and will be monetized within five years after completion of the spin-off.

The spin-off of 3M and its healthcare unit will facilitate each entity to flourish through better operational focus, capital allocation policies and financial flexibility. Solventum will serve a global addressable market worth about $93 billion, which is expected to grow in the range of 4-6% through 2026. The new entity will operate through four operating segments, which are Medical Surgical, Dental Solutions, Health Information Systems and Purification & Filtration.

MMM new 52 hi

I am optimistic about where we are headed from here? Am I alone with this sentiment?

ha roman after 26M in pocket becoming chairman of 3M board, obviously smelling rotten fish - after converting this from an innovative to xnovative company - what next

3M announces new CEO effective 5/1/24:

https://finance.yahoo.com/news/3m-announces-leadership-appointments-103000708.html 3M today announced that William M. "Bill" Brown is appointed chief executive officer, effective May 1, 2024. He succeeds Michael Roman, who is appointed to the role of Executive Chairman of the 3M Board of Directors, also effective May 1, 2024.

…Brown, 61, is the former Chairman of the Board and Chief Executive Officer of L3Harris Technologies, a global innovator in aerospace and defense technology solutions, where he served as chief executive officer and chairman, and then executive chair from June 2019 to June 2022. Brown previously served as chairman, president, and chief executive officer of Harris Corporation prior to its merger with L3 Technologies in 2019. He joined Harris Corporation in November 2011 as president and chief executive officer. Prior to Harris Corporation, Brown spent 14 years at United Technologies Corporation (UTC) serving in a variety of leadership roles.

Roman will continue to chair 3M's Board of Directors and provide insights from his more than 35 years with 3M to the company's strategic direction as executive chairman of the board. He has served as 3M's CEO since July 2018. Roman might not have been a bad CEO, but bad things happened to the company on his watch, so he gets the blame. The stock is +5% in PM trading.

Details of 3M’s SOLV spinoff finalized:

https://finance.yahoo.com/news/3m-board-directors-approves-spin-165500127.html

3M shareholders of record on 3/18/24 will receive 1 share of SOLV for every 4 shares of 3M. The SOLV shares will be distributed before the market open on 4/1/24.

This is a tax-exempt distribution for US residents.

Further details of 3M/SOLV capitalization:

SOLV will sell $8.4B of new debt, keeping $600M of the proceeds and paying $7.7B as a one-time (tax-free) dividend to 3M. (~$100M of the debt proceeds will go to underwriting fees.)

After the debt issuance and one-time payment to 3M, SOLV will have a debt/EBITDA ratio of ~3.5.

3M’s Solventum spin slated for 4/1/24—Nasdaq symbol=‘SOLV’—Investor Day 3/19/24:

https://finance.yahoo.com/news/3m-announces-filing-form-10-150000365.html

See #msg-173870424, #msg-173870432, and #msg-173870470 for related info.

Are market conditions such that 3M views the spinoff as a good way to pay down debt, or obtain funds for further innovation in the medical device sector or pharmaceutical/biotech sector? Funds for M/A with a target in mind? The spinoff will include a large one-time cash transfer from Solventum to the post-spin 3M. 3M will use this cash to pay down debt and/or to help fund the earplug and PFAS legal settlements.

The post-spin 3M will almost certainly refrain from material M&A for a few years; it will instead focus on re-igniting organic growth and paying the legal settlements mentioned above.

On the other hand, Solventum could be a takeover target for a company such as DHR or TMO.

3M will retain a 19.9% stake in Solventum following the spinoff. 3M plans to sell these shares gradually over a 5-year period.

These are the five focal areas for 3M’s healthcare business that will become part of Solventum; they comprise about 25% of 3M’s current company-wide sales:

https://engage.3m.com/purification

https://www.3m.com/3M/en_US/health-information-systems-us/

https://www.3m.com/3M/en_US/medical-us/ (surgical supplies and wound care)

https://www.3m.com/3M/en_US/medical-device-components-us/ (components for other companies’ medical devices)

https://www.3m.com/3M/en_US/oral-care-us/ (dentistry and othodontics)

What do you see as the main focus of that 3M healthcare unit? Consumer goods like Kenvue? Will 3M retain a substantial equity position like JNJ did with Kenvue? Are market conditions such that 3M views the spinoff as a good way to pay down debt, or obtain funds for further innovation in the medical device sector or pharmaceutical/biotech sector? Funds for M/A with a target in mind?

As noted, the point was to keep the streak alive.

This year, however, the streak will presumably be broken when 3M spins off its healthcare business, Solventum.

Wow, that's a puny increase. But thanks

3M increases dividend for 66th consecutive year:

https://investors.3m.com/news-events/press-releases/detail/1823/3m-board-declares-quarterly-dividend

The quarterly change was only a penny—from $1.50 to $1.51—so it’s clear that the increase is mainly to keep the streak alive.

At the current share price ($91.25), the new annualized payout of $6.04 equates to a dividend yield of 6.6%.

3M 4Q23 CC transcript:

https://finance.yahoo.com/news/q4-2023-3m-co-earnings-074558652.html

3M clarification—The 2024 guidance in the preceding post is on a pro forma basis including the healthcare segment being part of 3M for the full year. After the healthcare spinoff, slated for 1H24, 3M will issue updated 2024 guidance for the company excluding the healthcare segment.

3M reports 4Q23 results—issues (tepid) 2024 guidance:

https://investors.3m.com/news-events/press-releases/detail/1821/3m-delivers-strong-fourth-quarter-results-improves

4Q23 non-GAAP EPS—which excludes the cost of the announced earplug and PFAS settlements and related legal expenses —was $2.42, +11% YoY.

4Q23 sales were $8.0B, -0.8% YoY.

4Q23 organic sales growth (excluding FX, acquisitions, and divestitures) was -1.9% YoY.

3M issued 2024 non-GAAP EPS guidance—which excludes the cost of the announced earplug and PFAS settlements and related legal expenses—of $9.35-9.75, +1-6% YoY vs $9.24 in 2023.

2024 guidance for sales growth is 0.25-2.25%. 2024 guidance for organic sales growth is 0-2.0%.


3M’s healthcare spin-off, Solventum, is still slated to occur during 1H24; see #msg-173243340 for related info.


CC slides:
https://d1io3yog0oux5.cloudfront.net/_b81fdcf4b61b3aa85cc07b8e46d6f76a/3m/db/3222/30800/presentation/Q4+2023+Earnings+Slides.pdf

Financial statements:
https://d1io3yog0oux5.cloudfront.net/_b81fdcf4b61b3aa85cc07b8e46d6f76a/3m/db/3222/30800/financial_statement/Q4+2023+Financial+Statement+Information.pdf

~bought 1/26 $120 calls @.10c

3M earplug settlement gets 100% buy-in from pre-existing plaintiffs in class action:

https://finance.yahoo.com/news/combat-arms-earplug-settlement-achieves-114500350.html

See #msg-172712175 for background info.

I learned about 3M and some other top brands in the world from this article:https://www.zxmedppe.com/top-10-personal-protective-equipment-suppliers/

3M names healthcare spinoff, Solventum—a portmanteau of “solving” and “momentum”:

https://finance.yahoo.com/news/3m-reveals-solventum-name-planned-160100532.html

The healthcare segment comprises about 25% of 3M's worldwide sales, and it has a higher profit margin than the company as a whole.

3M has not yet disclosed whether the spin will be accomplished via a direct distribution to 3M shareholders or via a voluntary exchange offer; in either case the spin, which is planned for 1H24, is tax-free for 3M’s US shareholders. More info is available at https://www.3m.com/3M/en_US/health-care-us/?utm_term=hcbg-hcbs-na-en_us-ba-soft_spin-offa-vn-na-na-na-nov23-00000 .

3M 3Q23 CC transcript:

https://finance.yahoo.com/news/3m-company-nyse-mmm-q3-141732896.html

3M reports 3Q23 results—raises 2023 non-GAAP EPS guidance:

https://d1io3yog0oux5.cloudfront.net/_5cbb10b61269071d28abdd0a87b39497/3m/db/3222/30718/earnings_release/Q3+2023+Press+Release.pdf

3Q23 non-GAAP EPS was $2.68, up from $2.60 in 3Q22, and ahead of consensus expectations.

3M raised 2023 non-GAAP EPS guidance (which excludes the $10.3B+ PFAS settlement announced in June [#msg-172192818]) to $8.95-9.15 (from the prior range of $8.60-$9.10).

3M’s healthcare spin-off is now slated to occur during 1H24.


CC slides:
https://d1io3yog0oux5.cloudfront.net/_5cbb10b61269071d28abdd0a87b39497/3m/db/3222/30718/presentation/Q3+2023+Earnings+Presentation.pdf

Financial statements:
https://d1io3yog0oux5.cloudfront.net/_5cbb10b61269071d28abdd0a87b39497/3m/db/3222/30718/financial_statement/Q3+2023+Financial+Statement+Information.pdf

WSJ feature story on 3M:

https://www.wsj.com/business/3m-innovation-scientists-lawsuits-contamination-5a48d46f

https://www.openweb.com/share/2WMBUtXNRkflqADV4Jdam9PKqZ1

Saw it coming back in March. Closed my puts. Made a fortune.

"3M's legal troubles aren't over despite $18.5 billion in settlements"

"3M (MMM) is trying to put the country’s largest-ever mass tort case behind it. Even if it does, its legal problems are far from over.

The Minnesota conglomerate announced Tuesday it had agreed with plaintiffs attorneys to a $6 billion settlement that would end thousands of lawsuits from more than 260,000 veterans alleging earplugs made by a subsidiary caused hearing loss.

3M would make the payments between 2023 and 2029, splitting it between $5 billion in cash and $1 billion in stock, so long as the equity commitment is approved by the court."

https://finance.yahoo.com/news/3ms-legal-troubles-arent-over-despite-185-billion-in-settlements-115913197.html

3M’s earplug settlement_is_official—NPV=$5.3B pre-tax/$4.0-4.5B after-tax:

https://www.sec.gov/Archives/edgar/data/66740/000006674023000073/a829238kex-991.htm

• 3M will pay the earplug plaintiffs a cumulative $6.0B (consisting of $5B cash and $1B stock) over seven years (2023-2029). These payment obligations have a pre-tax net present value (NPV) of $5.3B (using a 5.6% discount rate).

• The anticipated schedule of settlement payments is set forth in slide #6 of today’s CC slide deck: https://d1io3yog0oux5.cloudfront.net/_301a30c91c73d8aa14cff777dcbd5df5/3m/db/3194/30703/presentation/CAE+Resolution+Presentation.pdf . 3M already reserved $1.1B for this liability, so a new $4.2B pre-tax charge to GAAP earnings will be made in 3Q23.

• 3M expects that the settlement payments will be fully tax-deductible, so the NPV of the settlement payments on an after-tax basis is in the $4.0-4.5B range.

• 3M hopes to recover as much as $1.5B of the settlement amount from liability insurance. Any recovery from insurance will reduce the settlement NPV; in the best-case scenario, the after-tax NPV of the settlement would be approximately $3B.

I expected a somewhat bigger bounce today, but I suppose that will come when the settlement deal is inked.

Great news for us!

3M close_to_inking $5.5B earplug settlement, according_to_sources:

https://www.wsj.com/business/3m-nears-settlement-for-about-5-5-billion-to-resolve-earplugs-complaints-94e9f31e 3M and plaintiffs attorneys are nearing a settlement that would resolve hundreds of thousands of claims by veterans that earplugs made by the company and a subsidiary failed to protect them from hearing loss. Under the terms being discussed, 3M would pay about $5.5 billion, people close to the discussions said.

…The earplug litigation has become the largest mass tort in U.S. history, with more than 300,000 claims. Veterans allege that 3M and Aearo Technologies, a company 3M acquired in 2008, produced faulty earplugs that failed to protect their hearing from noise damage when issued to them by the U.S. military. 3M is contesting the cases, and has said the earplugs work correctly when used with proper training.

The settlement amount being considered is substantially less than the $10 billion to $15 billion that some analysts have predicted the case would cost 3M. The possible settlement was earlier reported by Bloomberg News. This is hugely bullish for 3M if it pans out.

ZBH CEO will become CEO of 3M’s healthcare spinoff:

https://finance.yahoo.com/news/bryan-hanson-named-ceo-3ms-122300047.html

https://finance.yahoo.com/news/zimmer-biomet-announces-leadership-transition-122000860.html

Correction—3M’s healthcare spinoff is now slated for late 2023 or early 2024.

3M reports 2Q23 results—raises non-GAAP EPS guidance slightly…

PR:
https://investors.3m.com/news-events/press-releases/detail/1790/3m-reports-second-quarter-2023-results-proactive

CC slides:
https://d1io3yog0oux5.cloudfront.net/_42242654f7d5954ba2f4fd7c7044914f/3m/db/3222/30683/presentation/Q2+2023+Earnings+Presentation.pdf


2Q23 non-GAAP EPS was $2.17, down from $2.45 in 2Q22; however, 2Q23 cash flow from operations was +34% YoY due, in large part, to cost-cutting initiatives (#msg-171766597), which raised operating margins by 140 basis points YoY.

2Q23 sales of $8.33B were -4% YoY, but exceeded consensus expectations.

3M raised 2023 non-GAAP EPS guidance (which excludes the $10.3B+ PFAS settlement announced in June [#msg-172192818]) to $8.60-9.10 (up $0.10 from the prior range of $8.50-$9.00).

3M’s healthcare spin-off remains on track for closing in 2023.

3M settles PFAS litigation_vs_US_municipalities_for $10.3B NPV— payable_over_13 years—(2024-2036):

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000066740/000006674023000048/mmm-20230622.htm

The actual cumulative dollar amount to be paid (not discounted for NPV purposes) will be $10.5-12.5B.

"3M Can’t Resolve Mass Lawsuits Through Earplug Unit’s Bankruptcy, Judge Rules"

"Bankruptcy judge throws out 3M’s plan to use chapter 11 to resolve mass litigation alleging its combat earplugs harmed U.S. military service members"

https://www.wsj.com/articles/judge-throws-out-3m-earplug-units-bankruptcy-b486926f

$MMMW Mass Megawatts announced today about a new product. Based on my publicly available conversation , the company seems to be interested in 3M film which means that 3M might be in an important role to cheaper renewable energy and top corporate management may not know about it ( at least until maybe somebody tells them like perhaps someone in the sales department). Hopefully, they will know and maybe give a special effort to move the process in way that we cannot imagine).

I'm interested! Let's hear it!

3M is giving back some of Friday’s 8% gain because the settlement reported by Bloomberg is apparently not yet a fait accompli:

https://www.wsj.com/articles/trial-in-litigation-over-forever-chemicals-delayed-for-settlement-talks-2cfd56da

I am very interested

Please elaborate. TIA